Emtricitabine, Tenofovir alafenamide and Bictegravir

Therapeutic indications

Emtricitabine, Tenofovir alafenamide and Bictegravir is indicated for:

HIV-1 infection

Population group: only adults (18 years old or older)

Emtricitabine/tenofovir alafenamide/bictegravir combination is indicated for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Emtricitabine, Tenofovir alafenamide and Bictegravir is contraindicated in the following cases:

Lactation

Lactation

Patients with severe renal failure not receiving chronic haemodialysis

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Severe hepatic impairment

Hepatic failure stage IV

Rifampicin, St. John's wort

at least one of
Rifampicin
Hypericum perforatum (St John's Wort)

Antiretroviral medicinal products

at least one of
Nucleoside and nucleotide reverse transcriptase inhibitors
Antivirals for treatment of HIV infections, combinations

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: BIKTARVY Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈